Screening for high blood pressure: A review of the evidence for the U.S. Preventive Services Task Force

American Journal of Preventive Medicine

Volumn 25, Issue 2, 2003, Pages 151-158

  Sheridan, Stacey ^a,b   Pignone, Michael ^a   Donahue, Katrina ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLDOPA; RESERPINE;

ABSENTEEISM; ADULT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; HEALTH SERVICE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MASS SCREENING; MEDLINE; MENTAL HEALTH; META ANALYSIS; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; WELLBEING;

EID: 0043244911     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(03)00121-1     Document Type: Article

References (71)

1. Padwal R., Straus S.E., McAlister F.A. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension evidence based review . BMJ. 322:2001;977-980.
2. Kannel W.B. Blood pressure as a cardiovascular risk factor prevention and treatment . JAMA. 275:1996;1571-1576.
3. Klein R., Klein B.E., Moss S.E. The relation of systemic hypertension to changes in the retinal vasculature the Beaver Dam Eye Study . Trans Am Ophthalmol Soc. 95:1997;329-348. discussion 348-350.
4. Lederle F.A., Johnson G.R., Wilson S.E., et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 126:1997;441-449.
5. U.S. Preventive Services Task Force. Screening for hypertension. In: Guide to Clinical Preventive Services. 2nd ed. Washington DC: Office of Disease Prevention and Health Promotion, 1996:39-51.
6. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the U.S. Preventive Services Task Force a review of the process . Am J Prev Med. 20:(suppl 3):2001;21-35.
7. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
8. Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies . Lancet. 360:2002;1903-1913.
9. Benetos A., Thomas F., Bean K., Gautier S., Smulyan H., Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 162:2002;577-581.
10. Miura K., Daviglus M.L., Dyer A.R., et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men the Chicago Heart Association Detection Project in Industry . Arch Intern Med. 161:2001;1501-1508.
11. Ferrucci L., Furberg C.D., Penninx B.W., et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation. 104:2001;1923-1926.
12. Reeves R.A. Does this patient have hypertension? How to measure blood pressure. JAMA. 273:1995;1211-1218.
13. Birkett N.J. The effect of alternative criteria for hypertension on estimates of prevalence and control. J Hypertens. 15:1997;237-244.
14. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Washington DC: Office of Disease Prevention and Health Promotion, 1996:40.
15. McAlister F.A., Straus S.E. Evidence based treatment of hypertension. Measurement of blood pressure an evidence based review . BMJ. 322:2001;908-911.
16. Perry H.M. Jr, Miller J.P. Difficulties in diagnosing hypertension implications and alternatives . J Hypertens. 10:1992;887-896.
17. Ohkubo T., Imai Y., Tsuji I., et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements a pilot study in Ohasama . J Hypertens. 15:1997;357-364.
18. Myers M.G., Haynes R.B., Rabkin S.W. Canadian hypertension society guidelines for ambulatory blood pressure monitoring. Am J Hypertens. 12:(11 Pt 1):1999;1149-1157.
19. Staessen J.A., Beilin L., Parati G., Waeber B., White W. Task force IV Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring . Blood Press Monit. 4:1999;319-331.
20. Perloff D., Sokolow M., Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 249:1983;2792-2798.
21. Khattar R.S., Senior R., Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension a 10-year follow-up study . Circulation. 98:1998;1892-1897.
22. Redon J., Campos C., Narciso M.L., Rodicio J.L., Pascual J.M., Ruilope L.M. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension a prospective study . Hypertension. 31:1998;712-718.
23. Verdecchia P., Porcellati C., Schillaci G., et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 24:1994;793-801.
24. Ohkubo T., Imai Y., Tsuji I., et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion the Ohasama Study . Hypertension. 32:1998;255-259.
25. Khattar R.S., Swales J.D., Banfield A., Dore C., Senior R., Lahiri A. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. Circulation. 100:1999;1071-1076.
26. Staessen J.A., Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 282:1999;539-546.
27. Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of agreement between different measures of blood pressure in primary care and daytime ambulatory blood pressure. BMJ 2002;325:254.
28. Ogden L.G., He J., Lydick E., Whelton P.K. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 35:2000;539-543.
29. Staessen J.A., Gasowski J., Wang J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly meta-analysis of outcome trials . Lancet. 355:2000;865-872.
30. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153.
31. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) . JAMA. 283:2000;1967-1975.
32. Gueyffier F., Froment A., Gouton M. New meta-analysis of treatment trials of hypertension improving the estimate of therapeutic benefit . J Hum Hypertens. 10:1996;1-8.
33. Leiter L.A., Abbott D., Campbell N.R., Mendelson R., Ogilvie R.I., Chockalingam A. Lifestyle modifications to prevent and control hypertension. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ. 160:(suppl 9):1999;S7-S12.
34. Jones D.W. Body weight and blood pressure. Effects of weight reduction on hypertension. Am J Hypertens. 9:(suppl 8):1996;S50-S54.
35. Blumenthal J.A., Sherwood A., Gullette E.C., et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension effects on cardiovascular, metabolic, and hemodynamic functioning . Arch Int Med. 160:2000;1947-1958.
36. Cleroux J., Feldman R.D., Petrella R.J. Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ. 160:(suppl 9):1999;S21-S28.
37. Midgley J.P., Matthew A.G., Greenwood C.M., Logan A.G. Effect of reduced dietary sodium on blood pressure a meta-analysis of randomized controlled trials . JAMA. 275:1996;1590-1597.
38. Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002;325:628.
39. Ebrahim S., Smith G.D. Lowering blood pressure a systematic review of sustained effects of non-pharmacological interventions . J Public Health Med. 20:1998;441-448.
40. Fodor J.G., Whitmore B., Leenen F., Larochelle P. Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ. 160:(suppl 9):1999;S29-S34.
41. Cutler J.A., Follmann D., Allender P.S. Randomized trials of sodium reduction an overview . Am J Clin Nutr. 65:(suppl 2):1997;S643-S651.
42. Neaton J.D., Grimm R.H. Jr, Prineas R.J., et al. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA. 270:1993;713-724.
43. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 336:1997;1117-1124.
44. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 344:2001;3-10.
45. Whelton P.K., He J., Cutler J.A., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 277:1997;1624-1632.
46. Gilleran G., O'Leary M., Bartlett W.A., Vinall H., Jones A.F., Dodson P.M. Effects of dietary sodium substitution with potassium and magnesium in hypertensive type II diabetics a randomised blind controlled parallel study . J Hum Hypertens. 10:1996;517-521.
47. Fotherby M.D., Potter J.F. Long-term potassium supplementation lowers blood pressure in elderly hypertensive subjects. Int J Clin Pract. 51:1997;219-222.
48. Kawano Y., Minami J., Takishita S., Omae T. Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension. Am J Hypertens. 11:1998;1141-1146.
49. Xin X., He J., Frontini M.G., Ogden L.G., Motsamai O.I., Whelton P.K. Effects of alcohol reduction on blood pressure a meta-analysis of randomized controlled trials . Hypertension. 38:2001;1112-1117.
50. Linden W., Chambers L. Clinical effectiveness of non-drug treatment for hypertension a meta-analysis . Ann Behav Med. 16:1994;35-45.
51. Spence J.D., Barnett P.A., Linden W., Ramsden V., Taenzer P. Lifestyle modifications to prevent and control hypertension. (7) Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ. 160:(suppl 9):1999;S46-S50.
52. Batey D.M., Kaufmann P.G., Raczynski J.M., et al. Stress management intervention for primary prevention of hypertension detailed results from Phase I of Trials of Hypertension Prevention (TOHP-I) . Ann Epidemiol. 10:2000;45-58.
53. Whelton P.K., He J., Appel L.J., et al. Primary prevention of hypertension clinical and public health advisory from The National High Blood Pressure Education Program . JAMA. 288:2002;1882-1888.
54. Ameling E.H., de Korte D.F., Man in 't Veld A. Impact of diagnosis and treatment of hypertension on quality of life a double-blind, randomized, placebo-controlled, cross-over study of betaxolol . J Cardiovasc Pharmacol. 18:1991;752-760.
55. Mann A.H. The psychological effect of a screening programme and clinical trial for hypertension upon the participants. Psychol Med. 7:1977;431-438.
56. Ambrosio G.B., Dissegna L., Zamboni S., Santonastaso P., Canton G., Dal Palu C. Psychological effects of hypertension labeling during a community survey. A two-year follow-up. J Hypertens Suppl. 2:1984;S171-S173.
57. Rudd P., Price M.G., Graham L.E., et al. Consequences of worksite hypertension screening. Differential changes in psychosocial function. Am J Med. 80:1986;853-860.
58. Rudd P., Price M.G., Graham L.E., et al. Consequences of worksite hypertension screening. Changes in absenteeism. Hypertension. 10:1987;425-436.
59. Rastam L., Ryden L. Work absenteeism and well-being in patients treated for hypertension. Eur Heart J. 8:1987;1024-1031.
60. Polk B.F., Harlan L.C., Cooper S.P., et al. Disability days associated with detection and treatment in a hypertension control program. Am J Epidemiol. 119:1984;44-53.
61. Haynes R.B., Sackett D.L., Taylor D.W., Gibson E.S., Johnson A.L. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med. 299:1978;741-744.
62. Taylor D.W., Haynes R.B., Sackett D.L., Gibson E.S. Longterm follow-up of absenteeism among working men following the detection and treatment of their hypertension. Clin Invest Med. 4:(3-4):1981;173-177.
63. Charlson M.E., Alderman M., Melcher L. Absenteeism and labelling in hypertensive subjects. Prevention of an adverse impact in those at high risk. Am J Med. 73:1982;165-170.
64. Johnston M.E., Gibson E.S., Terry C.W., et al. Effects of labeling on income, work and social function among hypertensive employees. J Chronic Dis. 37:1984;417-423.
65. Alderman M.H., Charlson M.E., Melcher L.A. Labeling and absenteeism the Massachusetts Mutual experience . Clin Invest Med. 4:(3-4):1981;165-171.
66. Alderman M.H., Melcher L.A. Occupationally-sponsored, community-provided hypertension control. J Occup Med. 25:1983;465-470.
67. Stenn P.G., Noce A., Buck C. A study of the labeling phenomenon in school children with elevated blood pressure. Clin Invest Med. 4:(3-4):1981;179-181.
68. Harlan L.C., Polk B.F., Cooper S., et al. Effects of labeling and treatment of hypertension on perceived health. Am J Prev Med. 2:1986;256-261.
69. Mulrow C.D., Pignone M. How do we best individualize treatment for patients based on their cardiovascular risk profile? Mulrow C.D. Evidence-based Hypertension. 2001;117-130 BMJ Publishing Group, London.
70. Hyman D.J., Pavlik V.N. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 345:2001;479-486.
71. U.S. Department of Health and Human Services. Healthy people 2010. with understanding and improving health and objectives for improving health, 2nd ed. Washington DC: U.S. Government Printing Office, 2000.